• Skip to main content
  • Skip to primary sidebar
Pediatric Pulmonology: The Remaining Barriers to Normalcy in Cystic Fibrosis

The Remaining Barriers to Normalcy in Cystic Fibrosis

  • Issues
  • Resources
  • About
  • Contact
  • Search
November 2019

The Remaining Barriers to Normalcy in Cystic Fibrosis V

Mucus obstruction and inflammation in early cystic fibrosis lung disease: Emerging role of the IL‐1 signaling pathway

By Anita Balázs MD, PhD; Marcus A. Mall MD

Mucus plugging constitutes a nutrient‐rich nidus for a bacterial infection that has long been recognized as a potent stimulus for neutrophilic airway inflammation driving progressive lung damage in people with cystic fibrosis (CF). However, mucus plugging and neutrophilic…

[Read More]

Cystic fibrosis precision therapeutics: Emerging considerations

By Disha Joshi MSc; Annette Ehrhardt PhD; Jeong S. Hong PhD; Eric J. Sorscher MD

Small molecules that address fundamental defects underlying cystic fibrosis (CF), including modulators such as the approved drugs ivacaftor, lumacaftor, tezacaftor, and elexacaftor, have advanced dramatically over the past few years and are transforming care and prognosis among individuals…

[Read More]

Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy

By Lisa Saiman MD, MPH

Currently, available single and dual‐combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies have favorably altered the life course of individuals with cystic fibrosis (CF) by decreasing morbidities and increasing survival. However, even with CFTR modulator use, questions…

[Read More]

Off‐label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis

By Cameron J. McKinzie PharmD, BCPPS, BCPS, CPP; Lori Chen BScPhm; Kim Ehlert PharmD; Alison G. Grisso PharmD, BCPPS; Alaina Linafelter PharmD; Lisa Lubsch PharmD, BCPPS, AE‐C; Catherine E. O'Brien PharmD; Alice C. Pan PharmD, BCPPS; Brittany A. Wright PharmD, BCACP; E. Claire Elson PharmD, BCPPS

Management of infections in patients with cystic fibrosis (CF) presents challenges for healthcare providers, including the eradication of initial acquisition, treatment of acute exacerbations, and chronic infection with suppressive therapy. Inhaled antimicrobial therapy for infections in patients with…

[Read More]

Anti‐inflammatories and mucociliary clearance therapies in the age of CFTR modulators

By Lucy Perrem MD, MSc; Felix Ratjen MD, PhD

Cystic fibrosis (CF) is a genetic and life‐limiting disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. This multi‐system disease is characterized by progressive lung disease and pancreatic insufficiency amongst other manifestations. CFTR primarily functions…

[Read More]

Nutrition in cystic fibrosis: From the past to the present and into the future

By Kimberly Altman MS; Catherine M. McDonald PhD; Suzanne H. Michel MPH; Karen Maguiness MS

Nutritional management is an integral part of multidisciplinary care for persons with cystic fibrosis. This review will look at how nutrition care has evolved over time. In addition, we will look at how some newer therapies impact nutrition…

[Read More]

The demographics of adverse outcomes in cystic fibrosis

By Meghan E. McGarry MD, MAS; Wadsworth A. Williams II MA; Susanna A. McColley MD

Understanding variability in cystic fibrosis (CF) health outcomes requires an understanding of factors that go far beyond Cystic Fibrosis Transmembrane Receptor (CFTR) function caused by different gene mutations. Social and environmental factors that influence health have a significant…

[Read More]

Mucus, mucins, and cystic fibrosis

By Cameron Bradley Morrison BSPH; Matthew Raymond Markovetz PhD; Camille Ehre PhD

Cystic fibrosis (CF) is both the most common and most lethal genetic disease in the Caucasian population. CF is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and is characterized by the accumulation of…

[Read More]

« Previous Issue
The Remaining Barriers to Normalcy in Cystic Fibrosis IV - November 2018
Next Issue »
Remaining Barriers to Normalcy in Cystic Fibrosis VI - February 2021

Primary Sidebar

PP Cover - November 2018

Pediatric Pulmonology

The Remaining Barriers to Normalcy in Cystic Fibrosis I

October 2015 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis II

October 2016 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis III

November 2017 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis IV

November 2018 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis V

November 2019 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VI

February 2021 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VII

February 2022 · View Articles

Most Viewed Articles

  • Rapid therapeutic advances in CFTR modulator science

  • Reevaluating approaches to cystic fibrosis pulmonary exacerbations

  • Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors

  • Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy

  • Inflammation in cystic fibrosis: An update

Quiz and Survey

Test your knowledge and help shape future editions of "The Remaining Barriers to Normalcy." Participate in our Quiz and Survey »

This website is made possible by an educational grant from Vertex Pharmaceuticals Incorporated.

Vertex

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2018-2025 John Wiley & Sons, Inc. All Rights Reserved.
The content on this site is intended for health professionals.
Wiley